and excess mortality rates are relatively low. Even in these situations, though, the relative force of competing causes of mortality can be determined using the technique. Although one might wonder whether a two-part DEALE would have helped to improve accuracy or diminish biases, such maneuvers would raise another question: "At what point in time should one separate the two parts?" The message here is that more complex models are often more accurate, or at least appear to be. The tradeoff between simplicity and accuracy is common in decision modeling. Here, the clinician must ask: when is the simple approximation good enough, and when
A Call to Standardize Measures for Judging the Efficacy of Interventions to Aid Patients' Decision Making
In the past 20 years, we have witnessed a groundswell of studies evaluating various methods of presenting information about clinical options and outcomes to assist patients and their practitioners in weighing the benefits and risks. As the research evolves from the communication lab to the bedside, a key challenge is selecting the evaluation criteria for judging efficacy. In this issue, Edwards and Elvnl summarize the criteria used in previous studies, noting that there has been an expansion in focus from cognitive measures (knowledge, risk perceptions) and behavioral measures (decisions, intentions, and adherence behavior) to affective measures (anxiety, satisfaction, decisional conflict, assessment of the information and decision-making process). One of their frustrations in trying to judge the efficacy of patient-communication interventions has been the uneven and non-standardized use of evaluation measures. They conclude that progress in the research and the eventual uptake of efficacious interventions will be hampered unless researchers use standardized, validated measures.
There has never been a better time to work on this issue. The groundwork has been laid with the development of several conceptual frameworks, clinical interventions, evaluation measures and tri-als. The AHCPR has commissioned one review' and the Cochrane Review Group on Consumers and Communication has organized a series of systematic overviews.3 There are at least two active research interest groups on shared decision making to provide a forum for the debate -the Society for Medical Decision Making and the International Society for Technology Assessment in Health Care. Interest is also spreading to the practice arena. At least three clinical journals have planned special issues on risk communication and shared decision making (the British Medical Journal, the Journal of the National Cancer Institute, and Effective Clinical Practice). Moreover, the National Committee on Quality Assurance HEDIS measure, which is used by over 90% of U.S. Health Plans, is expanding its criteria (e.g., for managing menopause) to include the quality of personalized counseling that takes into account patients' personal risks and values.
Therefore, we will soon be in a position to take stock of lessons learned from the initial attempts to evaluate decision-supporting interventions. In particular, we need to know how the measures relate to one another and how sensitive they are in detecting change over time and between interventions.
I am not as optimistic as Edwards and Elwyn that the affective measures will be more sensitive than the others will. My hunch is that predominantly cognitive interventions are still likely to have predominantly cognitive effects. Those decisions that are usually associated with strong affective effects may respond favorably to cognitive interventions, and possibly more so to cognitive interventions with augmented support and coaching. And behavioral change will depend on whether the behavior is being driven predominantly by factors that are modifiable by the interventions.
Reaching consensus on standardized measures will be challenging because of the multiplicity of motivations, objectives, and conceptual frameworks used in developing (and therefore evaluating) the interventions. Entwistle et al.4 have begun to clarify this issue by classifying potential effects of interventions on decision making and health outcomes depending on the model of patient involvement (1, shared decision making; 2, individual informed choice; 3, professional as agent for the patient; 4, promotion of rational decision making; or 5, promotion of a particular choice). For example, one indicator of efficacy using model 5 may be patient compliance with a recommended option, whereas in model 4, an intervention that increases the selection of options that maximize the patients' expected utility may be judged successful. Entwistle et al. also acknowledge5 that promoting "evidence-informed patient choice" is seen by some as the desired end, whereas others see it as a means to other desirable outcomes, such as greater clinical effectiveness, health gain, individually appropriate utilization, reduced expenditures on inappropriate interventions, reduced litigation, etc.
Clearly, the perspective taken by the developer or the potential user will affect one's list of standard-ized criteria for evaluation. However, even if we narrowed the debate to essential criteria for valuebased choices using a non-directive model, several issues emerge. Which ones are essential to include in the developmental studies and in the clinical trials? How independent is one criterion from another? Are some measures surrogates for others? What is a clinically important difference?
As we begin to consider these issues, it is my hope that we can reach a consensus on standardized measures in a period shorter than the 20 years it took us to get this far.
